Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma

被引：0

作者：

Ravi Potluri

Sandip Ranjan

Hitesh Bhandari

Helen Johnson

Andriy Moshyk

Srividya Kotapati

机构：

[1] SmartAnalyst Inc.,

[2] SmartAnalyst India Pvt. Ltd.,undefined

[3] Bristol-Myers Squibb,undefined

[4] Bristol-Myers Squibb,undefined

来源：

Experimental Hematology & Oncology | / 8卷

关键词：

Advanced melanoma; Melanoma; Nivolumab; Ipilimumab; Healthcare cost comparison; CheckMate 067; NCT01844505;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, Jedd D.
Kluger, Harriet
Callahan, Margaret K.
Postow, Michael A.
Rizvi, Naiyer A.
Lesokhin, Alexander M.
Segal, Neil H.
Ariyan, Charlotte E.
Gordon, Ruth-Ann
Reed, Kathleen
Burke, Matthew M.
Caldwell, Anne
Kronenberg, Stephanie A.
Agunwamba, Blessing U.
Zhang, Xiaoling
Lowy, Israel
Inzunza, Hector David
Feely, William
Horak, Christine E.
Hong, Quan
Korman, Alan J.
Wigginton, Jon M.
Gupta, Ashok
Sznol, Mario
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02): : 122 - 133
[22] Ipilimumab plus nivolumab for advanced melanoma
Hassel, Jessica C.
LANCET ONCOLOGY, 2016, 17 (11): : 1471 - 1472
[23] Nivolumab plus Ipilimumab in Advanced Melanoma
Santhosh, Akhil
NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (12): : 1245 - 1246
[24] Repeated Response and severe Side Effects with Nivolumab and Ipilimumab and Ipilimumab Monotherapy, but not with Pembrolizumab, in a Patient with mucosal Melanoma
Lehner, G. M.
Moehn, N.
Ivanyi, P.
Skripuletz, T.
Beutel, G.
Satzger, I.
Gutzmer, R.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 70 - 71
[25] Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Wolchok, Jedd D.
Chiarion-Sileni, Vanna
Gonzalez, Rene
Grob, Jean-Jacques
Rutkowski, Piotr
Lao, Christopher D.
Cowey, C. Lance
Schadendorf, Dirk
Wagstaff, John
Dummer, Reinhard
Ferrucci, Pier Francesco
Smylie, Michael
Butler, Marcus O.
Hill, Andrew
Marquez-Rodas, Ivan
Haanen, John B. A. G.
Guidoboni, Massimo
Maio, Michele
Schoffski, Patrick
Carlino, Matteo S.
Lebbe, Celeste
McArthur, Grant
Ascierto, Paolo A.
Daniels, Gregory A.
Long, Georgina, V
Bas, Tuba
Ritchings, Corey
Larkin, James
Hodi, F. Stephen
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) : 127 - +
[26] A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor (GIST).
Singh, Arun S.
Chmielowski, Bartosz
Hecht, J. Randolph
Rosen, Lee S.
Chow, Warren Allen
Wang, Xiaoyan
Brackert, Sandra
Adame, Carlos
Bovill, John
Schink, Elena
Douek, Michael
Chantharasamee, Jomjit
Wong, Karlton
Eilber, Frederick C.
Glaspy, John A.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[27] COST EFFECTIVENESS OF NIVOLUMAB-IPILIMUMAB COMBINATION THERAPY COMPARED TO MONOTHERAPY FOR METASTATIC MELANOMA FROM A US SOCIETAL PERSPECTIVE
Tran, D. M.
McDowell, L. C.
Oh, A.
Barcelon, J. A.
Keyvani, D.
Merino, O.
Wilson, L.
VALUE IN HEALTH, 2016, 19 (03) : A124 - A124
[28] Neoadjuvant Ipilimumab/Nivolumab combination in locally advanced or oligometastatic melanoma
Ferrucci, Pier Francesco
Lanfrancone, Luisa
Mazzarella, Luca
Nezi, Luigi
Duso, Bruno Achutti
Manzo, Teresa
Lotti, Fiorenza
Gandini, Sara
Orsolini, Gianmarco
Pennacchioli, Elisabetta
Gnagnarella, Patrizia
Fierro, Maria Teresa
Senetta, Rebecca
Riviello, Concetta
Caliendo, Virginia
Quaglino, Pietro
Mazzarol, Giovanni
Bonizzi, Giuseppina
Cocorocchio, Emilia
JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (SUPPL 1)
[29] COST-EFFECTIVENESS OF NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA
Tibet, B.
VALUE IN HEALTH, 2018, 21 : S45 - S45
[30] Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal
Wan, M. T.
Ming, M. E.
BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (02) : 296 - 300

← 1 2 3 4 5 →